Results 191 to 200 of about 100,222 (232)

Genomic characterization of invasive <i>Streptococcus pneumoniae</i> isolates from a southern Taiwan medical centre, 2015-2023. [PDF]

Microb Genom
Liu P, Venero AK, Tran T, Metcalf BJ, Chochua S, Li Y, Huang YF, Lee MS.   +7 more
europepmc   +1 more source

Association between concomitant use of vancomycin-piperacillin/tazobactam and acute kidney injury in real-world setting. [PDF]

Front Physiol
Wang CH, Xia HJ, Fu YP, Shen NN, Fu YM.
europepmc   +1 more source

Prophage-Derived Endolysin E1 Synergizes with Meropenem Against <i>Acinetobacter baumannii</i>. [PDF]

Microorganisms
Wang J, Bai J, Li Y, Hu R, Yang H, Hu S, Ni W.   +6 more
europepmc   +1 more source

Emergence of KPC-producing <i>Pseudomonas aeruginosa</i> in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam. [PDF]

Antimicrob Agents Chemother
Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, Taltavull B, Tarriño-León M, Gallardo-García MdM, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, Moscoso M, Beceiro A, Oliver A, Bou G, Arca-Suárez J.   +13 more
europepmc   +1 more source

Draft genome sequence of a KPC-2-producing, meropenem-durlobactam non-susceptible <i>Klebsiella pneumoniae</i> ST11-KL64 clinical isolate. [PDF]

Microbiol Resour Announc
Wen H, Feng Y, Zong Z.
europepmc   +1 more source

Authors' response to comment on evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation. [PDF]

Int J Clin Pharm
Lewis SJ, Bauman AJ, Caiazza OG, Wan N, Payer S, Pauly OG, Shoemaker S.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Meropenem

Reactions Weekly, 2022
  +5 more sources

Meropenem

Reactions Weekly, 2023
  +6 more sources

Meropenem / Meropenem-vaborbactam

2017
Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms, the clinical reliance on meropenem and other carbapenems increased after their introduction ...
Peleg, A. Y., Harris, P.
openaire   +2 more sources